190 results
424B5
GERN
Geron Corp.
30 Mar 22
Prospectus supplement for primary offering
5:15pm
and meaningful clinical benefit to lower risk MDS patients, given their chronic anemia and the debilitating impact of serial RBC transfusions, and suggests … and Investigational Treatments
Chronic anemia is the predominant clinical problem in patients who have lower risk MDS. Typically, these patients are treated
424B5
GERN
Geron Corp.
29 Mar 22
Prospectus supplement for primary offering
4:05pm
would provide significant and meaningful clinical benefit to lower risk MDS patients, given their chronic anemia and the debilitating impact of serial … .
Certain Other Approved and Investigational Treatments
Chronic anemia is the predominant clinical problem in patients who have lower risk MDS. Typically
8-K
EX-99.1
29n3fy 4mco
11 Mar 21
Geron Corporation Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
4:20pm
424B5
ngf4ep
26 May 20
Prospectus supplement for primary offering
9:01am
424B5
ptdoy7j8y 78qtc60cnj
21 May 20
Prospectus supplement for primary offering
4:20pm
8-K
EX-99.1
j2qbj94
18 Dec 19
Geron Conducts End of Phase 2 Meeting for Imetelstat in Relapsed/Refractory Myelofibrosis
5:20pm